193 related articles for article (PubMed ID: 17654590)
1. Response of choline metabolites to docetaxel therapy is quantified in vivo by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P NMR spectroscopy of cell extracts.
Morse DL; Raghunand N; Sadarangani P; Murthi S; Job C; Day S; Howison C; Gillies RJ
Magn Reson Med; 2007 Aug; 58(2):270-80. PubMed ID: 17654590
[TBL] [Abstract][Full Text] [Related]
2. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.
Morse DL; Carroll D; Day S; Gray H; Sadarangani P; Murthi S; Job C; Baggett B; Raghunand N; Gillies RJ
NMR Biomed; 2009 Jan; 22(1):114-27. PubMed ID: 19016452
[TBL] [Abstract][Full Text] [Related]
3. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
[TBL] [Abstract][Full Text] [Related]
4. Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.
Grinde MT; Skrbo N; Moestue SA; Rødland EA; Borgan E; Kristian A; Sitter B; Bathen TF; Børresen-Dale AL; Mælandsmo GM; Engebraaten O; Sørlie T; Marangoni E; Gribbestad IS
Breast Cancer Res; 2014 Jan; 16(1):R5. PubMed ID: 24447408
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
[TBL] [Abstract][Full Text] [Related]
6. Quantification of phosphocholine and glycerophosphocholine with 31P edited 1H NMR spectroscopy.
Loening NM; Chamberlin AM; Zepeda AG; Gonzalez RG; Cheng LL
NMR Biomed; 2005 Nov; 18(7):413-20. PubMed ID: 16075415
[TBL] [Abstract][Full Text] [Related]
7. Quantitative (31)P HR-MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts.
Esmaeili M; Bathen TF; Engebråten O; Mælandsmo GM; Gribbestad IS; Moestue SA
Magn Reson Med; 2014 Jun; 71(6):1973-81. PubMed ID: 23878023
[TBL] [Abstract][Full Text] [Related]
8. 17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.
Brandes AH; Ward CS; Ronen SM
Breast Cancer Res; 2010; 12(5):R84. PubMed ID: 20946630
[TBL] [Abstract][Full Text] [Related]
9. Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.
Jordan BF; Black K; Robey IF; Runquist M; Powis G; Gillies RJ
NMR Biomed; 2005 Nov; 18(7):430-9. PubMed ID: 16206237
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cells.
Ward CS; Eriksson P; Izquierdo-Garcia JL; Brandes AH; Ronen SM
PLoS One; 2013; 8(4):e62610. PubMed ID: 23626839
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging.
Canese R; Pisanu ME; Mezzanzanica D; Ricci A; Paris L; Bagnoli M; Valeri B; Spada M; Venditti M; Cesolini A; Rodomonte A; Giannini M; Canevari S; Podo F; Iorio E
NMR Biomed; 2012 Apr; 25(4):632-42. PubMed ID: 22020805
[TBL] [Abstract][Full Text] [Related]
12. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy.
Muruganandham M; Alfieri AA; Matei C; Chen Y; Sukenick G; Schemainda I; Hasmann M; Saltz LB; Koutcher JA
Clin Cancer Res; 2005 May; 11(9):3503-13. PubMed ID: 15867253
[TBL] [Abstract][Full Text] [Related]
13. Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models.
Amstalden van Hove ER; Blackwell TR; Klinkert I; Eijkel GB; Heeren RM; Glunde K
Cancer Res; 2010 Nov; 70(22):9012-21. PubMed ID: 21045154
[TBL] [Abstract][Full Text] [Related]
14. In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts.
Esmaeili M; Moestue SA; Hamans BC; Veltien A; Kristian A; Engebråten O; Maelandsmo GM; Gribbestad IS; Bathen TF; Heerschap A
J Magn Reson Imaging; 2015 Mar; 41(3):601-9. PubMed ID: 24532410
[TBL] [Abstract][Full Text] [Related]
15. 31P MRSI and 1H MRS at 7 T: initial results in human breast cancer.
Klomp DW; van de Bank BL; Raaijmakers A; Korteweg MA; Possanzini C; Boer VO; van de Berg CA; van de Bosch MA; Luijten PR
NMR Biomed; 2011 Dec; 24(10):1337-42. PubMed ID: 21433156
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells.
Gillies RJ; Barry JA; Ross BD
Magn Reson Med; 1994 Sep; 32(3):310-8. PubMed ID: 7984063
[TBL] [Abstract][Full Text] [Related]
17. High-resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma.
Valonen PK; Griffin JL; Lehtimäki KK; Liimatainen T; Nicholson JK; Gröhn OH; Kauppinen RA
NMR Biomed; 2005 Jun; 18(4):252-9. PubMed ID: 15884096
[TBL] [Abstract][Full Text] [Related]
18. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
[TBL] [Abstract][Full Text] [Related]
19. Association of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status with total choline concentration and tumor volume in breast cancer patients: an MRI and in vivo proton MRS study.
Sah RG; Sharma U; Parshad R; Seenu V; Mathur SR; Jagannathan NR
Magn Reson Med; 2012 Oct; 68(4):1039-47. PubMed ID: 22213087
[TBL] [Abstract][Full Text] [Related]
20. Proof-of-the-Concept Study on Mathematically Optimized Magnetic Resonance Spectroscopy for Breast Cancer Diagnostics.
Belkić D; Belkić K
Technol Cancer Res Treat; 2015 Jun; 14(3):277-97. PubMed ID: 25246518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
